Literature DB >> 28042644

Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Ana M Ramos-Leví1, Mónica Marazuela2.   

Abstract

Comorbidities related to the cardiovascular system are one of the most prevalent in patients with acromegaly, and contribute to an increased risk of morbidity and all-cause mortality. Specifically, hypertension, cardiomyopathy, heart valve disease, arrhythmias, atherosclerosis, coronary artery disease, and cardiac dysfunction may be frequent findings. Although the underlying physiopathology for each comorbidity may not be fully elucidated, uncontrolled growth hormone/insulin-like growth factor 1 excess, age, prolonged disease duration, and coexistence of other cardio-vascular risk factors are significant influencing variables. A simple diagnostic approach to screen for the presence of these comorbidities may allow prompt treatment and arrest the progression of cardiac abnormalities. In this article, we revise the most prevalent cardiovascular comorbidities and their pathophysiology in acromegalic patients, and we address some recommendations for their prompt diagnosis, management and treatment. Strengths and pitfalls of different diagnostic techniques that are currently being used and how different treatments can affect these complications will be further discussed.

Entities:  

Keywords:  acromegalic cardiomyopathy; acromegaly; acromegaly cardiovascular comorbidities; hypertension; pegvisomant; radiotherapy; somatostatin analogs; valve disease

Mesh:

Substances:

Year:  2017        PMID: 28042644     DOI: 10.1007/s12020-016-1191-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  106 in total

1.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

3.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

4.  The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.

Authors:  M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

5.  Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.

Authors:  Letizia Maria Fatti; Massimo Scacchi; Elisabetta Lavezzi; Francesca Pecori Giraldi; Martina De Martin; Paola Toja; Georgios Michailidis; Marco Stramba-Badiale; Francesco Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  2006-11       Impact factor: 3.478

Review 6.  Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

Authors:  Patrick Maison; Anne-Isabelle Tropeano; Isabelle Macquin-Mavier; Andrea Giustina; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

7.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Authors:  J Ayuk; R N Clayton; G Holder; M C Sheppard; P M Stewart; A S Bates
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

8.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

9.  Mortality in acromegaly: a 20-year follow-up study.

Authors:  Elina Ritvonen; Eliisa Löyttyniemi; Pia Jaatinen; Tapani Ebeling; Leena Moilanen; Pirjo Nuutila; Ritva Kauppinen-Mäkelin; Camilla Schalin-Jäntti
Journal:  Endocr Relat Cancer       Date:  2016-05-16       Impact factor: 5.678

10.  Investigation of early atherosclerotic changes in acromegalic patients.

Authors:  I Kartal; H Oflaz; B Pamukçu; M Meriç; F Aral; N Ozbey; F Alagöl
Journal:  Int J Clin Pract       Date:  2008-04-16       Impact factor: 2.503

View more
  17 in total

Review 1.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

Review 2.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

Review 3.  Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2018-02-07       Impact factor: 3.633

4.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05

5.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

Review 6.  Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.

Authors:  Maryam Heidarpour; Davood Shafie; Ashraf Aminorroaya; Nizal Sarrafzadegan; Ziba Farajzadegan; Rasool Nouri; Arash Najimi; Christina Dimopolou; Gunter Stalla
Journal:  J Res Med Sci       Date:  2019-04-26       Impact factor: 1.852

7.  Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies.

Authors:  Chengxian Yang; Ge Li; Shenzhong Jiang; Xinjie Bao; Renzhi Wang
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

8.  The right atrium in acromegaly-a three-dimensional speckle-tracking echocardiographic analysis from the MAGYAR-Path Study.

Authors:  Árpád Kormányos; Anita Kalapos; Péter Domsik; Nándor Gyenes; Nóra Ambrus; Zsuzsanna Valkusz; Csaba Lengyel; Attila Nemes
Journal:  Quant Imaging Med Surg       Date:  2020-03

9.  Cardiac Abnormalities in Acromegaly Patients: A Cardiac Magnetic Resonance Study.

Authors:  Xiaopeng Guo; Jian Cao; Peijun Liu; Yihan Cao; Xiao Li; Lu Gao; Zihao Wang; Ligang Fang; Zhengyu Jin; Yining Wang; Bing Xing
Journal:  Int J Endocrinol       Date:  2020-02-14       Impact factor: 3.257

10.  Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population

Authors:  Mustafa Can; Muhammet Kocabaş; İlker Çordan; Hatice Çalışkan Burgucu; Melia Karaköse; Mustafa Kulaksızoğlu; Feridun Karakurt
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.